The 20 Best Drug Induced Dyskinesia Doctors Near Me in Ann Arbor, MI

Henry L. Paulson, M.D., Ph.D., is the Lucile Groff Professor of Neurology for Alzheimer's Disease and Related Disorders in the Department of Neurology at the University of Michigan. Dr. Paulson joined the U-M faculty in 2007, and he currently directs the Michigan Alzheimer’s Disease Center (MADC) and co-direct the U-M Protein Folding Diseases Initiative.Dr. Paulson received his medical degree and doctorate in Cell Biology from Yale University in 1990. He then completed a neurology residency and neurogenetics/movement disorders fellowships at the University of Pennsylvania. In 1997, he joined the Neurology faculty at the University of Iowa, where he remained until 2007.Dr. Paulson's research and clinical interests concern the causes and treatment of age-related neurodegenerative diseases, with an emphasis on polyglutamine diseases, Alzheimer's disease and frontotemporal dementia. In 1997, his lab described abnormal protein aggregates in the polyglutamine diseases, which now are recognized as a pathological hallmark in this important class of inherited diseases. Using test tube, cell-based and animal models, he has contributed to advances in the understanding of various neurodegenerative diseases. His lab also has helped pioneer the use of gene silencing methods as potential therapy for the many neurological disorders caused by toxic mutant genes.Nationally, Dr. Paulson has directed popular courses at the American Academy of Neurology meetings, serves on the scientific advisory boards of numerous disease-related national organizations, and is past Chair of the Board of Scientific Counselors at the National Institute for Neurological Disorders and Stroke at the National Institutes of Health.Among his awards, Dr. Paulson is an Ellison Medical Foundation New Scholar in Aging, a semifinalist for the W.M. Keck Foundation Young Scholars in Medical Research, and a recipient of the Paul Beeson Physician Faculty Scholar in Aging Award from the American Federation for Aging Research. Dr. Paulson is rated as an Elite provider by MediFind in the treatment of Drug Induced Dyskinesia. He is also highly rated in 41 other conditions, according to our data. His clinical expertise encompasses Spinocerebellar Ataxia Type 3, Olivopontocerebellar Atrophy, Spinocerebellar Ataxia, and Drug Induced Dyskinesia. Dr. Paulson is board certified in Neurology.

Vikram Shakkottai is a Neurologist practicing medicine in Ann Arbor, Michigan. Dr. Shakkottai is rated as an Elite provider by MediFind in the treatment of Drug Induced Dyskinesia. He is also highly rated in 72 other conditions, according to our data. His clinical expertise encompasses Olivopontocerebellar Atrophy, Spinocerebellar Ataxia, Spinocerebellar Ataxia Type 1, and Drug Induced Dyskinesia.

Wayne Cornblath is a Neurologist and an Ophthalmologist practicing medicine in Ann Arbor, Michigan. Dr. Cornblath is rated as a Distinguished provider by MediFind in the treatment of Drug Induced Dyskinesia. He is also highly rated in 31 other conditions, according to our data. His clinical expertise encompasses Optic Neuritis, Myasthenia Gravis, Increased Intracranial Pressure, and Benign Essential Blepharospasm.

Kara J. Wyant, MD, is a clinical lecturer in the Department of Neurology. She received her bachelor’s degrees in mathematics and music from Ohio Northern University, and medical degree from the University of Toledo College of Medicine. Dr. Wyant completed her neurology residency training at the University of Pittsburgh Medical Center, where she served as chief resident from 2015-2016. She is currently pursuing a fellowship in movement disorders at the University of Michigan focusing on the medical and surgical management of patients with Parkinson disease and parkinsonism. Dr. Wyant also serves on the neurohospitalist service at University Hospital, and participates in teleneurology consults for MidMichigan Health. Dr. (md) is rated as a Distinguished provider by MediFind in the treatment of Drug Induced Dyskinesia. She is also highly rated in 31 other conditions, according to our data. Her clinical expertise encompasses Drug Induced Dyskinesia, Parkinson's Disease, Movement Disorders, Dopa-Responsive Dystonia, and Deep Brain Stimulation. Dr. (md) is board certified in Neurology.

Peter K. Todd, M.D., Ph.D., is an assistant professor in the Department of Neurology in the University of Michigan Medical School.Dr. Todd earned his Bachelor of Science degree in 1994 from the University of California, San Diego. He then entered the Medical Science Training Program at the University of Wisconsin at Madison, where he completed his doctorate in 2002 and medical degree in 2004. His Ph.D research focused on synaptic defects in Fragile X Syndrome, a common inherited cause of cognitive impairment in children.He completed his internship and residency at the Hospital of the University of Pennsylvania in Philadelphia. While there, he did research on the role of the ubiquitin proteasome system and autophagy in Spinal and Bulbar Muscular Atrophy, a polyglutamine disorder, and Fragile X Tremor Ataxia Syndrome (FXTAS). He came to the U-M in 2008 for a clinical and research fellowship in movement disorders and neurogenetics.Todd joined the U-M faculty in 2010 as an assistant professor in movement disorders and neurogenetics, working in the laboratory of Henry L. Paulson, M.D., Ph.D., in the Center for Neurodegenerative Research.His current research is focused on the mechanisms underlying RNA-mediated neurodegeneration in FXTAS and myotonic dystrophy, and how these mechanisms may overlap and inform our understanding of other neurodegenerative disorders. He also sees patients with movement disorders and inherited neurological disease.Dr. Todd has received several academic awards, including a Howard Hughes Undergraduate Research Fellowship, the Francis M. Forester Prize for promise as an academic neurologist, the Samuel Ziritzky Prize for most outstanding research by a neurology resident at Penn and prizes for excellence in research at the International Conference on Unstable Microsatellites in Human Disease, and the U-M neuroscience day. Most recently, Dr Todd received the S. Weir Mitchell Alliance award from the American Academy of Neurology which each year recognizes one early investigator physician scientist who has made important contributions to basic science in neurological disorders.A member of the American Medical Association and the American Academy of Neurology, he has served as an ad-hoc reviewer for the Journal of Biological Chemistry, Neurology, Proceedings of the National Academy of Sciences, Neuron, Science and Human Molecular Genetics.His bibliography includes several peer-reviewed papers, editorials, book reviews and chapters, abstracts and online. Dr. Todd is rated as a Distinguished provider by MediFind in the treatment of Drug Induced Dyskinesia. He is also highly rated in 49 other conditions, according to our data. His clinical expertise encompasses Fragile X Syndrome, Fragile XE Syndrome, Hereditary Ataxia, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). Dr. Todd is board certified in Neurology.

Kelvin L. Chou, M.D. is a Clinical Professor in the Departments of Neurology and Neurosurgery at Michigan Medicine and was the inaugural Thomas H. and Susan C. Brown Early Career Professor in Neurology. Dr. Chou has been named to the Best Doctors of America list since 2011 and sees all patients with movement disorders (i.e. Parkinson’s disease, tremors, dystonia, Huntington disease), though he has a particular interest in Parkinson’s disease (PD) and deep brain stimulation (DBS). Dr. Chou serves as Co-Director of the STIM (Surgical Therapies Improving Movement) Program and his research focus is on improving the ability to treat movement disorders patients through DBS. He is also an experienced clinical trialist, conducting numerous clinical trials on new therapies for PD, essential tremor and Huntington disease. He directs the Neurology Clinical Trials Organization (NeCTO) and is Lead Medical Director of the Neuroscience and Sensory Clinical Trials Support Unit (CTSU) at Michigan Medicine. He has published over 100 peer-reviewed journal articles, review articles or book chapters on PD and related movement disorders. A strong patient advocate, Dr. Chou is the Education and Outreach Core Director for the U-M Udall Center of Excellence for PD Research and serves on the Professional Advisory Board of the Michigan Parkinson Foundation and the Medical Advisory Board of the International Essential Tremor Foundation (IETF). He has also authored a book for patients and families called Deep Brain Stimulation: A New Life for People with Parkinson's, Dystonia and Essential Tremor. Dr. Chou is rated as a Distinguished provider by MediFind in the treatment of Drug Induced Dyskinesia. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Parkinson's Disease, Movement Disorders, Essential Tremor, Drug Induced Dyskinesia, and Deep Brain Stimulation. Dr. Chou is board certified in Neurology.

Dr. Praveen Dayalu is an Associate Professor and the Thomas H. and Susan C. Brown Early Career Professor of Neurology at the University of Michigan. He graduated from medical school at Case Western Reserve University in Cleveland, in 2002, and then completed neurology residency and movement disorders fellowship at Michigan, in 2006. His main focus is clinical management of movement disorders, especially Parkinson disease. His research interests are in Huntington disease and Multiple System Atrophy. He is the Director of the Movement Disorders Fellowship and trains fellows, residents, and medical students. Dr. Dayalu is rated as a Distinguished provider by MediFind in the treatment of Drug Induced Dyskinesia. He is also highly rated in 42 other conditions, according to our data. His clinical expertise encompasses Huntington Disease, Movement Disorders, Drug Induced Dyskinesia, and Parkinson's Disease. Dr. Dayalu is board certified in Neurology.

After graduating from Tehran University of Medical Sciences in 1990, Dr. Sohrab spent time in Spinal Cord Injury Centers of Iran, in multiple capacities, organizing care and educating different levels of practitioners in providing care for veterans of war. He then spent a few years of general practice, in different parts of Iran, dedicated to providing medical care and organizing Public Health Services, in rural areas. Dr. Sohrab has been practicing, and teaching, general Neurology at the University of Michigan, since 2012. Dr. Sohrab is rated as an Experienced provider by MediFind in the treatment of Drug Induced Dyskinesia. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Migraine, Vertigo, Migraine with Brainstem Aura, and Trigeminal Neuralgia.

Jack M. Parent, M.D., is a professor of neurology, director of the Neurodevelopment and Regeneration Laboratory, and co-director of the Comprehensive Epilepsy Center in the University of Michigan Medical School.His current research interests include neural stem cell transplantation to treat brain injury and neurodegeneration, and the modification of adult neural stem cells to promote brain repair after stroke or prevent epilepsy.Dr. Parent earned a Bachelor of Arts degree, with distinction, in human biology from Stanford University and his medical degree from the Yale University School of Medicine. He completed a medical internship and neurology residency at the University of California, San Francisco (UCSF), where he was selected chief resident. He stayed at UCSF for clinical fellowship training in epilepsy and clinical neurophysiology, and postdoctoral training in neuroscience research.An internationally recognized research leader in the fields of neural stem cell biology, regeneration after brain injury and epilepsy, Dr. Parent established the Neurodevelopment and Regeneration Laboratory at the U-M in 2000.Dr. Parent is a member of the Epilepsy Foundation of America Research Council, the Medical Advisory Board of the Global Ischemia Foundation, the Independent Science Review Panel of the New Jersey Commission on Brain Injury Research, and the National Scientific Advisory Council of the American Federation for Aging Research. He also serves as an associate editor of Neuroscience Letters, and is on the editorial boards of Experimental Neurology and Epilepsy Currents.He has received several awards for his research, including a Junior Investigator Award from the American Epilepsy Society, a Paul Beeson Physician Faculty Scholars in Aging Award, a Dreifuss-Penry Epilepsy Award from the American Academy of Neurology, and a Grass Foundation Award in Neuroscience from the American Neurological Association. Dr. Parent is rated as an Experienced provider by MediFind in the treatment of Drug Induced Dyskinesia. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Myoclonic Epilepsy, Epilepsy, Epilepsy with Myoclonic-Atonic Seizures, and Dravet Syndrome. Dr. Parent is board certified in Neurology and Clinical Neurophysiology.

Punithavathy Vijayakumar is a Neurologist and a Sleep Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Vijayakumar is rated as an Experienced provider by MediFind in the treatment of Drug Induced Dyskinesia. She is also highly rated in 29 other conditions, according to our data. Her clinical expertise encompasses Multiple Sclerosis (MS), Obstructive Sleep Apnea, Transient Ischemic Attack (TIA), and Migraine. Dr. Vijayakumar is board certified in Clinical Neurophysiology, Neurology, Neuromuscular Medicine, Sleep Medicine, and Vascular Neurology.

From 2013 to 2015 Dr. De Lott studied for and obtained an MS, Health and Healthcare Research at the University of Michigan, Rackham Graduate School in Ann Arbor, Michigan. Dr. Delott is rated as an Advanced provider by MediFind in the treatment of Drug Induced Dyskinesia. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Optic Neuritis, Papilledema, Pseudotumor Cerebri Syndrome, and Increased Intracranial Pressure. Dr. Delott is board certified in Neurology.

Nicolaas Bohnen is a Neurologist and a Nuclear Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Bohnen is rated as an Advanced provider by MediFind in the treatment of Drug Induced Dyskinesia. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Parkinson's Disease, Movement Disorders, Osteopenia, Melorheostosis, and Deep Brain Stimulation.

Roger L. Albin, M.D. (Residency 1986), is a professor of neurology, associate chair for research and co-director of the Movement Disorders Clinic in the Department of Neurology in the University of Michigan Medical School. In addition, he serves as chief of neuroscience research at the VA Ann Arbor Healthcare System Geriatric Research Education and Clinical Center.Dr. Albin joined the U-M faculty in 1988 as an instructor in the Department of Neurology. He was promoted to assistant professor in 1989; associate professor in 1994; and achieved his current rank of full professor in 2000.After completing his undergraduate degree at Oberlin College in Ohio, Dr. Albin earned his medical degree from the University of Pittsburgh School of Medicine in 1982, and completed his residency at the University of Michigan in 1986. He also completed a movement disorders fellowship in 1988 under Drs. Anne Young and John Penney.His clinical and research interests include the underlying neurobiologic causes of the clinical features of movement disorders, basal ganglia structure and function, Parkinson's disease, Tourette syndrome, dementias, dystonias and Huntington's disease. His laboratory is pursuing work on basic mechanisms of neurodegeneration in Huntington disease using mouse genetic models. Dr. Albin also has participated in neuroprotective clinical trials for both Huntington's disease and Parkinson's disease.The present focus of Dr. Albin's group is uncovering the basis for non-motor (sleep disorders, depression, dementia, autonomic dysfunction) problems in Parkinson's disease. He is very interested in applying positron emission tomography (PET) imaging methods to improve diagnosis of dementing disorders like Alzheimer's disease. The hope is that understanding how specific brain alterations cause specific clinical features will lead to improved treatments.Dr. Albin currently serves as a site investigator for the National Institutes of Health (NIH) Exploratory Trials in Parkinson disease (NET-PD) initiative. His work is supported by grants from the NIH, the Michael J. Fox Foundation and the High Q Foundation.A member of the American Academy of Neurology, the American Association for the Advancement of Science, the American Neurologic Association, and the Society for Neuroscience, Dr. Albin currently serves on the editorial boards of Experimental Neurology, Neurology and Neurobiology of Disease. Dr. Albin is rated as an Advanced provider by MediFind in the treatment of Drug Induced Dyskinesia. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Movement Disorders, Parkinson's Disease, Huntington Disease, Dementia, and Deep Brain Stimulation. Dr. Albin is board certified in Neurology.

Sami Barmada, M.D., Ph.D. is an assistant professor of neurology at the University of Michigan Medical School. His clinical interests center around patients with dementia and motor neuron disease, and he sees patients at the Cognitive Disorders Clinic in the University of Michigan’s East Ann Arbor location.His research focuses on the pathologic overlap between amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), and how we can take advantage of the convergence to identify new and effective therapies for these devastating disorders.After graduating from the University of Pittsburgh, Pennsylvania, in 1998 with a major in Molecular Biology, Biochemistry, and a focus in Conceptual Foundations of Medicine, Dr. Barmada went on to the Medical Scientist Training Program at Washington University in St. Louis School of Medicine. For his graduate work, he constructed a transgenic mouse model of Creutzfeldt-Jacob disease with Dr. David Harris, and used these animals to track the deposition of misfolded prion protein within the nervous system of infected animals. For this work, Dr. Barmada earned earned the Poletsky Award from the Alzheimer’s Disease Research Center in St. Louis, Missouri, and was elected as a Olin Medical Scientist Fellow at Washington University School of Medicine.Dr. Barmada received his M.D. and Ph.D. in 2006, and completed an Internal Medicine internship at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, Missouri, before moving to the University of California, San Francisco (UCSF), Medical Center for his residency in Neurology. Dr. Barmada served one year as Chief Resident in the Department of Neurology, focusing on resident education. He was also a house-staff nominee to the Alpha-Omega-Alpha honor society. During his residency, Dr. Barmada became involved in research with Dr. Steve Finkbeiner of the Gladstone Institutes, a pioneer in neuronal models of neurodegenerative disease and novel technologies to study these models. Dr. Barmada finished his residency in 2010 and spent one year working with Dr. Finkbeiner as a research fellow, before becoming a Staff Scientist at the Gladstone Institutes and a Clinical Instructor at UCSF. In 2013, Dr. Barmada became an Assistant Professor of Neurology at the University of Michigan, where he divides his time between the Cognitive Disorders Clinic and the laboratory. Dr. Barmada is rated as an Advanced provider by MediFind in the treatment of Drug Induced Dyskinesia. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Frontotemporal Dementia, and Dementia. Dr. Barmada is board certified in Neurology.

Sharan Srinivasan is a Neurologist practicing medicine in Ann Arbor, Michigan. He has been practicing medicine for over 10 years. Dr. Srinivasan is rated as an Advanced provider by MediFind in the treatment of Drug Induced Dyskinesia. He is also highly rated in 108 other conditions, according to our data. His clinical expertise encompasses Hereditary Ataxia, Olivopontocerebellar Atrophy, Spinocerebellar Ataxia Type 4, and Spinocerebellar Ataxia Type 5. Dr. Srinivasan is board certified in Neurology.

Daniel Leventhal, MD, PhD is an Assistant Professor of Neurology in the Movement Disorders division. His primary clinical duties are at the VA Ann Arbor Healthcare System, where he co-directs the Deep Brain Stimulation program for Movement Disorders. His practice there focuses on the treatment of Parkinson Disease, tremor disorders, dystonia, and related syndromes.Dr. Leventhal completed his undergraduate degree in Physics at The College of William and Mary in Virginia in 1995, and a combined MD/PhD program (PhD in Biomedical Engineering) at Case Western Reserve University in 2004. He then pursued medical internship and Neurology residency at the University of Michigan (completed in 2008), followed by a combined Movement Disorders and postdoctoral research fellowship at Michigan. In 2012, he joined the Neurology faculty at Michigan, and joined the VA as a staff Neurologist in 2015.Dr. Leventhal also directs a basic science laboratory at the University of Michigan. His research interests lie primarily in understanding the brain circuit abnormalities that contribute to the clinical manifestations of Parkinson Disease and related disorders. His laboratory uses advanced in vivo neuronal recordings and manipulations in rats and mice as they learn and perform complex behaviors.Dr. Leventhal is a member of the American Academy of Neurology, Movement Disorders Society, American Neurological Association, and Society for the Neural Control of Movement. Dr. Leventhal is rated as an Advanced provider by MediFind in the treatment of Drug Induced Dyskinesia. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Movement Disorders, Parkinson's Disease, Drug Induced Dyskinesia, Chorea, and Deep Brain Stimulation. Dr. Leventhal is board certified in Neurology.

Dr. Sean Smith is the Medical Director of Michigan Medicine's Cancer Rehabilitation program, with a clinical emphasis on restoring function and reducing symptom burden in patients with a history of cancer. In addition to chairing the AAPM&R's Cancer Rehabilitation Physician Consortium and the multi-site research collaborative, the Cancer Rehabilitation Metrics Consortium, he serves on the editorial board of the Journal of Clinical Oncology, and is a Deputy Associate Editor for Supportive Care in Cancer. He has published numerous peer-reviewed manuscripts and has conducted educational seminars on cancer rehabilitation on three continents. Dr. Smith is rated as an Advanced provider by MediFind in the treatment of Drug Induced Dyskinesia. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Chronic Graft Versus Host Disease (cGvHD), Foot Drop, Lymphedema, and Femoral Nerve Dysfunction. Dr. Smith is board certified in Physical Medicine & Rehab.

Dr. Schmidt attended medical school at Michigan State University, and completed her residency training in PM&R at the University of Pittsburgh Medical Center where she also served as chief resident. Dr. Schmidt's clinical responsibilities include outpatient practice focusing on transition into adulthood for pediatric patients with disabilities, cerebral palsy, amyotrophic lateral sclerosis and other neuromuscular conditions. Dr. Schmidt is rated as an Advanced provider by MediFind in the treatment of Drug Induced Dyskinesia. She is also highly rated in 49 other conditions, according to our data. Her clinical expertise encompasses Dysferlinopathy, Spinal Muscular Atrophy (SMA), Spinal Muscular Atrophy Type 3, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease).

Mala Young is a Physiatrist practicing medicine in Ann Arbor, Michigan. Dr. Young is rated as an Advanced provider by MediFind in the treatment of Drug Induced Dyskinesia. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Drug Induced Dyskinesia, Meige Syndrome, Dopa-Responsive Dystonia, and Familial Paroxysmal Nonkinesigenic Dyskinesia.

Dr. Ayyangar developed and directs several Pediatric Rehabilitation programs at the University of Michigan including the Pediatric Rehabilitation Medicine Fellowship Program, and the intrathecal baclofen program. She was also instrumental in developing the injection under sedation program for botulinum toxin and phenol injections and initiating the use of US guidance for injections in the pediatric population. She has a particular affinity for the management of children with complex needs and is currently actively involved in the Pediatric Palliative Care Service, and is board certified in Hospice and Palliative Medicine (as well as pediatrics, PM&R, and pediatric rehabilitation medicine.) She has served on the AAPM&R Board of Governors as well as several academy committees. She was Vice Chair and Chair of the Council for Pediatric Rehabilitation/Developmental Disabilities and received the 2015 AAPM&R Outstanding Council Service Award. Dr. Ayyanagar has made national and international presentations on topics related to spasticity management and cerebral palsy and has received several honors including recognition as one of the Best Doctors in America as a pediatric specialist in 2013, 2014 and 2015 by US News and World Report. Dr. Ayyangar is rated as an Advanced provider by MediFind in the treatment of Drug Induced Dyskinesia. She is also highly rated in 17 other conditions, according to our data. Her clinical expertise encompasses Cerebral Palsy, Spastic Diplegia Infantile Type, Spasticity, and Focal Dystonia. Dr. Ayyangar is board certified in Pediatric Rehabilitation Medicine and Physical Medicine & Rehab.